Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.59 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | HINT1 | P49773 | 1/20 | 0.54 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | KRAS | P01116 | 8/20 | 0.51 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318870 | 1.00 | NT5E (0.59) | NT5ETGM2HINT1STING1PDE3B | |
| SCHEMBL13396564 | 1.00 | NT5E (0.59) | NT5ETGM2HINT1STING1PDE3B | |
| SCHEMBL3313815 | 0.91 | NT5E (0.54) | NT5ETGM2HINT1STING1PDE3B | |
| SCHEMBL3313826 | 0.91 | NT5E (0.54) | NT5ETGM2HINT1STING1PDE3B | |
| SCHEMBL3313838 | 0.91 | NT5E (0.54) | NT5ETGM2HINT1STING1PDE3B | |
| SCHEMBL3314655 | 0.89 | NT5E (0.52) | NT5ETGM2HINT1STING1PDE3B | |
| SCHEMBL3314652 | 0.89 | NT5E (0.52) | NT5ETGM2HINT1STING1PDE3B | |
| SCHEMBL13396510 | 0.89 | NT5E (0.52) | NT5ETGM2HINT1STING1PDE3B | |
| SCHEMBL26347612 | 0.88 | P2RY2 (0.58) | NT5ETGM2HINT1STING1PDE3B | |
| SCHEMBL6900891 | 0.85 | AHCY (0.63) | NT5ETGM2HINT1STING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | NT5E 226/4885TGM2 487/4885HINT1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.